Literature DB >> 15692543

Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial.

Elina Nikanne1, Hannu Kokki, Juha Salo, Timo-Jussi Linna.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of celecoxib and ketoprofen in pain management during tonsillectomy in 120 patients. STUDY DESIGN AND
SETTING: The study was randomized, double-blind, and placebo-controlled with parallel groups. Sixty minutes before anesthesia induction and 12 hours after, the patients received a 200-mg celecoxib, a 100-mg ketoprofen, or a placebo capsule. After discharge, patients were prescribed either celecoxib or ketoprofen capsules to be taken every 12 hours.
RESULTS: During the first 24 hours, the need for rescue analgesic was less in the ketoprofen-group (5 [1-9]) doses (median [range]) than in the placebo-group (6 [1-13]) ( P = 0.021), but similar to the celecoxib-group (5 [2-14]). After discharge, the cessation of pain during eating occurred earlier in the celecoxib-treated patients, after 10 (1-17) days, than in the ketoprofen-treated patients, after 12 (1-21) days, ( P = 0.008). One celecoxib-treated patient and 6 ketoprofen-treated patients ( P = 0.013) needed electrocautery to stop postoperative bleeding.
CONCLUSION: Ketoprofen provided a better initial analgesic efficacy but after discharge the recovery with celecoxib was faster and the incidence of secondary hemorrhages was lower. SIGNIFICANCE: Celecoxib seems to be more effective and safe than ketoprofen for pain management after discharge in patients with tonsillectomy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15692543     DOI: 10.1016/j.otohns.2004.09.005

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  8 in total

Review 1.  Nonsteroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy.

Authors:  Sharon R Lewis; Amanda Nicholson; Mary E Cardwell; Gretchen Siviter; Andrew F Smith
Journal:  Cochrane Database Syst Rev       Date:  2013-07-18

2.  Stability of celecoxib oral suspension.

Authors:  Ronald F Donnelly; Elena Pascuet; Carmen Ma; Régis Vaillancourt
Journal:  Can J Hosp Pharm       Date:  2009-11

3.  [Unexpected hemorrhage complications in association with celecoxib. Spontaneously reported case series after perioperative pain treatment in gynecological operations].

Authors:  T Stammschulte; K Brune; A Brack; H Augenstein; G Arends; U Gundert-Remy
Journal:  Anaesthesist       Date:  2014-12       Impact factor: 1.041

Review 4.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

Review 5.  Laparoscopic surgery: a narrative review of pharmacotherapy in pain management.

Authors:  Sari Sjövall; Merja Kokki; Hannu Kokki
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

6.  Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study.

Authors:  Kimmo Murto; Christine Lamontagne; Colleen McFaul; Johnna MacCormick; Kelly-Ann Ramakko; Mary Aglipay; David Rosen; Regis Vaillancourt
Journal:  Can J Anaesth       Date:  2015-04-07       Impact factor: 5.063

7.  Comparison of celecoxib and acetaminophen for pain relief in pediatric day case tonsillectomy: A randomized double-blind study.

Authors:  Mohammad Faramarzi; Sareh Roosta; Mohammad Hossein Eghbal; Bahar Nouri Rahmatabadi; Ali Faramarzi; Soliman Mohammadi-Samani; Mahmood Shishegar; Mohammad Ali Sahmeddini
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-10-27

8.  A single dose of celecoxib 200 mg improves postoperative analgesia provided via patient-controlled epidural technique after caesarean section.

Authors:  Paraskevi Matsota; Maria Nakou; Konstantinos Kalimeris; Chrisanthi Batistaki; Angeliki Pandazi; Georgia Kostopanagiotou
Journal:  Arch Med Sci       Date:  2012-10-16       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.